CAMP4 Therapeutics Corporation (CAMP)
NASDAQ
Healthcare
Biotechnology
$4.20
▲ +0.72%
Market Cap
$89.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.21
52-Wk Range
1.36-7.75
CEO
Joshua Mandel-Brehm
Country
US
Currency
USD
CAMP4 Therapeutics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $4.20, up 0.72% on the session, giving a market capitalisation of $89.2M. On trailing twelve-month figures it carries a trailing P/E of -1.85, a net margin of -2193.7%. Its beta of 0.21 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-1.85
Price / Sales
22.68
Price / Book
7.87
EV / EBITDA
0.15
Gross margin
76.2%
Operating margin
-1322.6%
Net margin
-2193.7%
Return on equity
—
Debt / equity
0.07
Current ratio
6.15
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
48
IPO date
2024-10-11
Headquarters
Cambridge, MA, US
About CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Comparable companies
CAMP4 Therapeutics Corporation is most often compared with the following Healthcare names:
More research on CAMP
Open full interactive analysis & DCF →